In a survey of patients with CML-CP, AEs were a major reason for missing doses¹

Many patients with CML skip doses without consulting their HCP because of how treatment makes them feel—despite the risk of decreased efficacy.^1-4

*In a US survey (70 patients, 30 physicians) investigating the unmet needs around CML and treatment switching in patients who had received 1 to 3 prior TKIs.¹

In a separate study, 52% said their treatment had interfered with their QOL during the preceding year.^5,†

^†Among 832 patients with CML who were experiencing low-grade AEs. Patients were treated for a median duration of 5.8 years.⁵

Patients with higher rates of adherence were more likely to achieve deeper responses³

For patients with an adherence rate of >90%, the 6-year probability of achieving MMR with a 1st TKI was 93.7%.³

Six-year probability of achieving MMR, MR4, and CMR in patients with CML on a 1st TKI with different levels of adherence³

A study of 87 patients with CML-CP who had achieved complete cytogenetic response had adherence monitored during a 3-month period by using a microelectronic monitoring device to determine the association between adherence and molecular response.³

Patients with an adherence rate of >85% had lower probability of progression on their 1st TKI⁶

24-month probability of EFS in patients with Ph+ CML-CP on a TKI and an adherence rate of ≤85% (n=18) or >85% (n=69)^6,‡

^‡In a study of 87 patients with CML, the relationship between adherence and probability of EFS were evaluated. Adherence levels were monitored using a medication event-monitoring (an electronic device fitted into the cap of a normal-looking medication bottle that automatically records each time the bottle is opened). After 3 months of monitoring, patients were followed subsequently for a median of 19 months (range, 14-24 months).⁶